fbpx

Medicines and reduced kidney function

Kidney hero image

People with reduced kidney function are at increased risk of experiencing medicine related harm. Reduced kidney function is a major risk factor for serious adverse drug reactions and is associated with poor outcomes include reduced quality of life, hospital admissions and death.1 In Australia, 1 in 3 people with reduced kidney function are prescribed medicines that are either inappropriately high doses or contraindicated due to kidney function.2 

 

The below resources and activities have been designed to assist pharmacists utilise medicine considerations as well as the specific patient and disease related considerations, to formulate appropriate dosing adjustment recommendations for those with reduce kidney function.  

Resources and activities

Link to Cumulative Medicines Webinar

Watch the recording of the webinar: Medicines and reduced kidney function.

Link to Pharmacist Quick Reference Guide on Cumulative Medicines

Access the Pharmacist Quick Reference Guide: Medicines and reduced kidney function.

Link to Pharmacist Case Series

Access the Pharmacist Case Series: optimise medicine dosing in reduced kidney function.

References: 

1. Laville S, Gras-Champel V, Hamroun A, Moragny J, Lambert O, Metzger M, et al. Kidney Function Decline and Serious Adverse Drug Reactions in Patients With CKD. Am J Kidney Dis. 2024;83(5):601-14. 

 

2. Castelino R, Saunder T, Kitsos A, Peterson G, Jose M, Wimmer B, et al. Quality use of medicines in patients with chronic kidney disease. BMC Nephrol. 2020;21(1):216. 

Medicines Advice Initiative Australia (MAIA) is provided to you by University of South Australia Quality Use of Medicines and Pharmacy Research Centre | In association with: Australian Medicines Handbook (AMH) | Drug and Therapeutics Information Service (DATIS) | Discipline of General Practice, University of Adelaide | National Aboriginal Community Controlled Health Organisation (NACCHO) | Pharmaceutical Society of Australia (PSA) | Council of Australian Therapeutic Advisory Groups (CATAG).  
MAIA is funded by the Australian Government through the Quality Use of Diagnostics, Therapeutics and Pathology Program. 
MAIA materials are adapted from the Veterans’ MATES program materials.  “This material is used under licence from the Australian Government, © Commonwealth of Australia, Department of Veterans’ Affairs 2023”. The views expressed in the MAIA materials do not necessarily represent the views of the Minister for Veterans’ Affairs or the Department of Veterans’ Affairs.  The Commonwealth does not give any warranty nor accept any liability in relation to the content or use of this material.”  
Department of veteran affairs logo

The Pharmaceutical Society of Australia (PSA) is the peak national professional pharmacy organisation, representing Australia's 37,000+ pharmacists in all sectors and across all locations, working in or towards a career in pharmacy. Registered training organisation code: 122206 ABN:49 008 532 072 ACN:008 532 072

In the spirit of reconciliation, the Pharmaceutical Society of Australia (PSA) acknowledges the Traditional Custodians of Country throughout Australia and their connections to land, sea and community. We pay our respect to their Elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today. We recognise that Aboriginal and Torres Strait Islander peoples were our first pharmacists.

© 2024 Pharmaceutical Society of Australia Ltd. All rights reserved.